DYN SEC Filings: 8-K, 10-Q, S-3 & 424B – Dyne Therapeutics

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 5, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Jul 29, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 11, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 2, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 5, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Jul 28, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Dyne Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Regulatory Progress for Z-Rostudirsen and Z-Basivarsen

Nov 5, 2026

8-K

Dyne Therapeutics Announces Positive One-Year Clinical Data for Z-Basivarsen (DYNE-101) in Myotonic Dystrophy Type 1

Sep 29, 2026

8-K

Dyne Therapeutics Reports Q2 2026 Financial Results and Regulatory Progress for DMD and DM1 Programs

Jul 29, 2026

8-K

Dyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock

Jul 22, 2026

8-K

FDA Accepts Dyne Therapeutics' BLA for Zeleciment Rostudirsen (DYNE-251) with Priority Review

Jul 20, 2026

8-K

Dyne Therapeutics Appoints Barry E. Greene to Board of Directors

Jun 22, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

REGISTERED OFFERING

Jul 22, 2026

424B5

PENDING FIXED PRICE OFFERING | Offering amount: $300,000,000 | Bank: Morgan Stanley, Jefferies, Evercore ISI, LifeSci Capital, Raymond James

Jul 21, 2026

424B5

FIXED PRICE OFFERING - COMMON STOCK | Offering amount: $350,000,014 | Shares: 18,980,478 | Price: $18.440 | Bank: Morgan Stanley, Jefferies, Stifel, Guggenheim Securities

Dec 10, 2025

424B5

PENDING FIXED PRICE OFFERING | Offering amount: $300,000,000 | Bank: Morgan Stanley

Dec 8, 2025

424B5

REGISTERED OFFERING

Jul 1, 2025

424B5

PENDING FIXED PRICE OFFERING

Jun 30, 2025

Registrations

TYPE

HEADLINE

FILED AT

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 23, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 23, 2026

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Apr 9, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 15, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 15, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 5, 2024

Ownerships

TYPE

HEADLINE

FILED AT

Kerr Douglas (Reporting)

Oct 22, 2026

Posner Brian S (Reporting)

Oct 6, 2026

144

Form 144 - Report of proposed sale of securities

Sep 8, 2026

144

Form 144 - Report of proposed sale of securities

Sep 8, 2026

Friedl-Naderer Johanna (Reporting)

Sep 8, 2026

Kerr Douglas (Reporting)

Sep 8, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Nov 18, 2021

CORRESP

Form CORRESP - Correspondence

Nov 15, 2021

LETTER

Form UPLOAD - SEC-generated letter

Nov 10, 2021

EFFECT

Form EFFECT - Notice of Effectiveness

Jan 21, 2021

CORRESP

Form CORRESP - Correspondence

Jan 19, 2021

CORRESP

Form CORRESP - Correspondence

Jan 19, 2021

Dyne Therapeutics, Inc. DYN · SEC Filings